MK-1064|cas 1207253-08-4|DC Chemicals

Cas No.:	1207253-08-4
Chemical Name:	Mk-1064
Synonyms:	MK-1064;MK1064;O812716S9E;5''-chloro-N-[(5,6-dimethoxypyridin-2-yl)methyl]-2,2':5',3''-terpyridine-3'-carboxamide;5-(5-Chloro-3-pyridyl)-N-((5,6-dimethoxy-2-pyridyl)methyl)-2-(2-pyridyl)pyridine-3-carboxamide;5''-Chloro-N-((5,6-dimethoxypyridin-2-yl)methyl)-2,2':5',3''-terpyridine-3'-carboxamide;CKTWQGHVNRYNCM-UHFFFAOYSA-N;Urokinase inhibitor 1;GTPL9306;BCP19608;BDBM50028059
SMILES:	ClC1=C([H])N=C([H])C(=C1[H])C1C([H])=NC(C2=C([H])C([H])=C([H])C([H])=N2)=C(C(N([H])C([H])([H])C2C([H])=C([H])C(=C(N=2)OC([H])([H])[H])OC([H])([H])[H])=O)C=1[H]
Formula:	C₂₄N₅O₃ClH₂₀
M.Wt:	461.9003
Sotrage:	4°C for 1 year, -20°C for more than 2 years

Description:

MK-1064 is a selective orexin 2 receptor antagonist (2-SORA) for the research of insomnia.target: 2-SORA [1]In vivo: MK-1064 promotes sleep and increases both rapid eye movement (REM) and non-REM (NREM) sleep in rats at OX2R occupancies higher than the range observed for dual orexin receptor antagonists. MK-1064 increases NREM and REM sleep in dogs without inducing cataplexy. The reference for animal administration is 30 mg/kg. [2]

Cat. No.	Product name	Field of application
DC5017	Suvorexant	Suvorexant (MK-4305) is a potent, selective, and orally bioavailable antagonist of OX1R and OX2R.Suvorexant is regulated as a Schedule IV compound in the United States. This product is intended for use in analytical forensic applications. This product is for research use only, not for any other purposes.
DC9966	MK-1064	MK-1064 is a selective orexin 2 receptor antagonist (2-SORA) for the research of insomnia.
DC8173	Lemborexant(E2006)	Lemborexant (E-2006) is a dual antagonist of the orexin OX1 and OX2 receptors which is under development for treatment of insomnia.
DC7692	Almorexant HCl (Act-078573)	Almorexant(ACT078573) is a potent and competitive dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist with Ki values of 1.3 and 0.17 nM for OX1 and OX2, respectively.